EFTA02572704

From: jeffrey E. <[email protected]> Sent: Wednesday, November 1, 2017 4:31 PM To: Masha Drokova; Steven Sinofsky Subject: Re: steve can you give some guidance On Wed, Nov 1, 2017 at 12:20 PM, =asha Drokova wrote: > > I'm looking to invest at the compa=y doing AI-based glucose monitoring system for people with diabetes. =We made tech evaluation, talked to a few experts and more a question about=the market and regulations. Likely no, because it's complex area= but still thinking of them. May be someone in your network who knows thi= area and can advise on this kind of tech? Center Health Deck: https://dri.e.google.com/file/d/085O93D3UArEbXBsdll4elVob0U/view chttps://drive.go=gle.com/file/d/085O93D3IJArEbX8sdll4elVob0U> </=pan> =br> Our memo: https://docs=google.com/document/d/1M7ZV7VEI8anb4EtYWFH2sacCm0PM6g1Al=wrIOtM <https://docs.google.com/document/d/1=72V7VEI8CTnb4EtYWFH2sq5dcCm0PM6g1AlcwrIOtM> Center Health is building an =1-based glucose monitoring system for the 1 in 11 Americans who suffe= from diabetes, based on machine learning and their personalized AI, =ria. Users subscribe to their disposable test strips, a $148/yr US market,=which are delivered monthly, as Aria learns about their diabetes and promp=s behavioral changes to lower blood sugar. The system is an orde= of magnitude cheaper than existing technologies, premised on leveraging d=ta to help users see what daily elements are affecting their blood su=ar, and predicting dangerous highs and lows before they happen. Pros — Existing glucometers from=big companies are very old-fashioned and outdated, those companies make th=ir revenue from overpriced strips — Direct competito=s, such as iHealth and Dario have negative customer reviews an= minor — Uses FDA-approved circuits to get the approval in a= automated manner <=ont face="Roboto-Regular"> Cons — Enormous pressure both from the industry players and companies=such as Apple and Google that try to develop non- invasive glucose monitori=g that will wipe out test strip products — Hardware =tartup without a product to sell yet, finalizing the development — Young team =C2 please note EFTA_R1_01742408 EFTA02572704 The information contained in t=is communication is confidential, may be attorney-client privileged, ma= constitute inside information, and is intended only for the use of =he addressee. It is the property of JEE Unauthorized use, disclosure=or copying of this communication or any part thereof is strictly prohib=ted and may be unlawful. If you have received this communication in =rror, please notify us immediately by return e-mail or by e-mail to [email protected]=m, and destroy this communication and all copies thereof, includ=ng all attachments. copyright -all rights reserved --001a113a26c077ebe8055cee6601-- conversation-id 25269 date-last-viewed 0 date-received 1509553874 flags 8590195713 gmail-label-ids 7 6 remote-id 764151 2 EFTA_R1_01742409 EFTA02572705